Oruka jumps as lead drug outperforms AbbVie's Skyrizi in early-stage trial
Source: SeekingAlpha
2025-09-17 08:46:48 ET
More on Oruka Therapeutics, AbbVie
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
- Short bets on S&P 500 Healthcare sector eases in August; MRNA stays most shorted stock
- AbbVie settles with generic drugmakers for key immunology drug Rinvoq
Read the full article on Seeking Alpha
For further details see:
Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
-0.97% G/L:
$224.48 Last:
1,406,476 Volume:
$226.89 Open:
ABBV Latest News
March 13, 2026 01:36:56 pm
Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
